Ginkgo Bioworks Holdings (DNA) Depreciation & Amortization (CF) (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $12.8 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 13.65% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.4 million (down 13.16% YoY) and the FY2025 annual result came in at $59.0 million, down 6.39% from the prior year.
• Depreciation & Amortization (CF) fell to $12.8 million in Q1 2026, from $13.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $21.1 million in Q3 2023 to a low of $8.9 million in Q3 2022.
• A 5-year average of $14.5 million and a median of $14.8 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 136.18% — and 2024, when it tumbled 32.12%.
• Tracing DNA's Depreciation & Amortization (CF) over 5 years: stood at $15.7 million in 2022, then declined by 18.06% to $12.8 million in 2023, then climbed by 21.93% to $15.7 million in 2024, then retreated by 12.71% to $13.7 million in 2025, then retreated by 6.32% to $12.8 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $12.8 million (Q1 2026), $13.7 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.